Once you are diagnosed with liver cancer, words like "surgery," "embolization," "targeted therapy," and "immunotherapy" come pouring out of your doctor's mouth all at once. When you actually hear them, your mind goes blank. The truth is that liver cancer treatment is not a single fixed path; it branches depending on the size and number of the tumors, liver function, whether blood vessels are invaded, and whether it has spread to other organs. If you just grasp the big picture of those branches, you can gauge roughly where you stand right now.
When it is caught relatively early, the first option to consider is removing the tumor directly. There is surgical resection to cut it out, radiofrequency ablation that uses a needle to apply heat and burn it away, and, if the conditions are right, even a liver transplant. Up to this point it is called "curative treatment," the stage where a complete cure can be aimed for. However, liver function has to be able to support it and the tumor's location matters, so it does not apply to everyone.
If the tumor has progressed a bit more or there are several of them, you move on to the embolization stage (such as TACE), which blocks the blood vessels feeding the liver to starve the tumor. But if it has traveled through the vessels and spread elsewhere, or if embolization does not control it well, this is where systemic drug treatment comes into play in earnest. That is targeted therapy and immunotherapy. The two work differently. A targeted drug pinpoints and blocks the signaling pathways that cancer cells use to grow and to build new blood vessels, while an immunotherapy drug blocks the route the cancer uses to deceive our immune cells and slip away, helping the immune system recognize and attack the cancer again.
These days the trend has settled on using the two together rather than separately. A combination regimen that adds a vessel-targeting drug to an immune-checkpoint inhibitor is often cited as the first-line treatment for advanced liver cancer. It essentially sets the stage for the immune system to attack the cancer well, and better responses than in the era of using just one drug have been reported. Of course, immunotherapy works well in some people and not in others, so if the first drug does not suit you, second- and third-line cards such as switching to a different targeted drug are also prepared.
The texture of the side effects also differs by drug. Targeted therapy tends to crack the skin of the hands and feet, raise blood pressure, and cause frequent diarrhea, while immunotherapy can cause inflammation-like reactions in the thyroid, liver, lungs, or intestines as the immune system becomes overactive. So instead of thinking "this is a bit odd, but shall I just put up with it," it is important to tell your medical team right away about changes such as fatigue, rash, or shortness of breath. When caught early, it can often be managed without having to stop the drug.
To sum up, it goes like this: in the early stage, remove the tumor directly; in the middle, embolization; once it has progressed beyond that, a targeted-plus-immune combination — that is the broad outline. That said, this is only meant to show you the overall map, and your own treatment is best decided sitting face to face with the attending physician who has reviewed your liver condition and all your test values. Take the flow written here lightly, just as something to help you gather questions for the clinic.